SARS-CoV-2-IN-110 (compound Bb1) is an inhibitor of SARS-CoV-2, demonstrating antiviral efficacy with an EC50 of 1.10 µM, and significantly reduced toxicity compared to Lapatinib. The compound exhibits a CC50 of greater than 100 µM against SARS-CoV-2, with a selectivity index (SI) exceeding 91.
Molekulargewicht:
498.94
Formel:
C28H20ClFN4O2
Target-Kategorie:
SARS-CoV
* Mehrwertsteuer und Versandkosten nicht enthalten. Irrtümer und Preisänderungen vorbehalten
